Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 10/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 2/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21125844 | 0.96 | HSD17B1 (0.44) | PDK2HSD17B1HSD17B2HPGDSFEN1 | |
| SCHEMBL19794372 | 0.96 | PDK2 (0.44) | PDK2HSD17B1HSD17B2FEN1 | |
| SCHEMBL12140657 | 0.90 | HSD17B1 (0.43) | PDK2HSD17B1HSD17B2HPGDS | |
| SCHEMBL19933646 | 0.90 | PDK2 (0.43) | PDK2HSD17B1HSD17B2FEN1 | |
| SCHEMBL6236658 | 0.87 | HSD17B1 (0.45) | PDK2HSD17B1HSD17B2 | |
| SCHEMBL18015500 | 0.87 | PDK2 (0.33) | PDK2HSD17B1HSD17B2HPGDSDYRK1A | |
| SCHEMBL22037979 | 0.87 | MEN1 (0.40) | PDK2HSD17B1HSD17B2LDHAHPGDS | |
| SCHEMBL22038510 | 0.86 | MEN1 (0.42) | PDK2LDHABAZ2B | |
| SCHEMBL13388812 | 0.86 | HSD17B1 (0.46) | PDK2HSD17B1HSD17B2LDHAHPGDS | |
| SCHEMBL22037501 | 0.85 | MEN1 (0.41) | PDK2LDHABAZ2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11024815-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| EP-3254317-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11024815-B2 | Metal complexes | EXOC4, EXOC3, TIMCC | PDK2 3655/4885HSD17B1 4860/4885HSD17B2 4834/4885 |
| US-20180026209-A1 | Metal Complexes | AP3M1, AP2M1, SOD1 | PDK2 2111/4885HSD17B1 4527/4885HSD17B2 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.